share_log

ECHOLIGHT ANNOUNCES MULTI-YEAR AGREEMENT WITH SIEMENS HEALTHINEERS

ECHOLIGHT ANNOUNCES MULTI-YEAR AGREEMENT WITH SIEMENS HEALTHINEERS

ECHOLIGHT宣佈與西門子醫療簽署多年協議
PR Newswire ·  11/18 22:59

HOUSTON, Nov. 18, 2024 /PRNewswire/ -- Echolight, a global innovator in bone densitometry, announced that it has signed an agreement enabling Siemens Healthineers to be a reseller of Echolight bone densitometers in support of their Women's Health solutions.

Echolight,全球骨密度技術創新者,宣佈已簽署協議,使西門子醫療可以成爲Echolight骨密度儀的經銷商,支持其婦女健康解決方案。

EchoStation from Echolight Medical
Echolight Medical的EchoStation

Echolight's REMS (Radiofrequency Echographic Multi Spectometry) innovative technology measures bone density and microarchitecture without using the radiation of traditional x-ray scans but instead through a simple ultrasound scan of axial anatomical sites such as the spine and femur. This radiation-free technology allows physicians to perform repeated scans for monitoring bone health over time. In addition, the ability to automatically exclude artifacts commonly present with other densitometry procedures yields a highly reliable diagnostic assessment.

Echolight的REMS(無輻射的射頻超聲多能譜)創新技術通過簡單的超聲掃描測量骨密度和微結構,而不使用傳統X射線掃描的輻射,而是通過對脊柱和股骨等軸向解剖部位進行超聲掃描。這種無輻射技術允許醫生隨時間監測骨骼健康,另外,自動排除其他骨密度程序中常見的僞影,提供高度可靠的診斷評估。

"Bone health is a serious problem here in the US. This agreement provides expanded provider and patient access to REMS technology in the US through ultrasound-based bone density scanning as another option in the effort to diagnose and monitor bone health. Echolight is pleased to support Siemens Healthineers in their focus on women's health and bone disease," explained Thomas J. McLaughlin, Executive Commercial Director, Echolight USA.

"骨密度在美國是一個嚴重的問題。該協議通過基於超聲的骨密度掃描作爲診斷和監測骨骼健康的另一選擇,爲提供者和患者在美國擴大對REMS技術的使用。Echolight很高興能支持西門子醫療在婦女健康和骨疾病方面的專注,"Echolight USA的執行商業董事Thomas J. McLaughlin解釋道。

Echolight's portable solution measures bone quantity and quality simultaneously, through evaluation of bone mineral density at the lumbar vertebrae (L1-L4) and the femoral neck providing all common parameters of the diagnosis of osteoporosis BMD (g/cm2), T-scores, and Z-score. It also measures fragility score through an independent assessment of internal bone structure to evaluate the risk of fracture in 5 years through dedicated statistical and spectral analysis. Siemens Healthineers will be offering the Echos Plus, Echostation, and Echohybrid Plus models.

Echolight的便攜式解決方案通過評估腰椎(L1-L4)和股骨頸骨密度,同時測量骨量和質量,提供骨質疏鬆症(BMD)的所有常見診斷參數,包括T-score、Z-score。它還通過獨立評估內部骨骼結構來測量脆性評分,通過專門的統計和頻譜分析評估未來5年骨折風險。西門子醫療將提供Echos Plus, Echostation和Echohybrid Plus型號。

For more information, visit the Echolight booth #1853 at the RSNA Annual Meeting.

欲了解更多信息,請訪問RSNA年會上Echolight展位#1853。

Echolight was established in Italy with head office in Lecce, and in 2020 opened its offices in the United States. Since then, its sales network has grown to more than 40 distributors and several hundreds of satisfied customers across the world who have adopted the innovative R.E.M.S. technology for assessing the bone condition of their patients.

Echolight成立於意大利,並在萊切設有總部,2020年在美國開設了辦事處。從那時起,其銷售網絡已擴展到40多家經銷商和數百名全球滿意的客戶,他們採用了創新的REmS技術來評估其患者的骨骼狀況。

Created as a spin-off of the Italian National Research Council, Echolight is at the forefront of medical innovation, introducing new cutting-edge solutions to contribute to human wellbeing. It has been awarded all the standard certificates: UNI CEI EN ISO 13485: 2016, Quality Management System UNI EN ISO 9001: 2015, CE mark, FDA clearance, and other major certificates worldwide for innovative solutions considered as the best practice in bone health for personalized medicine.

作爲意大利國家研究委員會的一個分支,Echolight 處於醫療創新的前沿,推出新的尖端解決方案,爲人類福祉做出貢獻。它獲得了所有標準證書:UNI CEI EN ISO 13485:2016,質量管理體系 UNI EN ISO 9001:2015,CE標誌,FDA許可,以及其他全球範圍內被視爲個性化醫學中骨骼健康最佳實踐的創新解決方案。

SOURCE Echolight Medical

資料來源 Echolight 醫療

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

想要您公司的新聞在PRNEWSWIRE.COM上特色呈現嗎?

440k+
440k+

Newsrooms &
新聞發佈室&

Influencers
影響力人士
9k+
9k+

Digital Media
數字媒體

Outlets
Outlets
270k+
270k+

Journalists
記者

Opted In
Opted In
GET STARTED
開始使用

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論